Prevalence, predictors and outcomes of thyroid dysfunction in patients with acute myocardial infarction: the ThyrAMI-1 study.


Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 12 06 2020
accepted: 25 08 2020
pubmed: 9 9 2020
medline: 26 11 2021
entrez: 8 9 2020
Statut: ppublish

Résumé

Thyroid dysfunction in patients with cardiac disease is associated with worse outcomes. This study aimed to evaluate the prevalence and analyse predictors and outcomes of thyroid dysfunction in patients presenting with an acute myocardial infarction (AMI). A prospective multicentre observational study of patients recruited from six acute hospitals within the North of England. Consecutive patients without previous thyroid disease presenting with both ST-elevation AMI (STEMI) and non-ST-elevation AMI (NSTEMI) were recruited to the Thyroxine in Acute Myocardial Infarction 1 (ThyrAMI-1) cohort study between December 2014 and 2016. Thyroid profile, standard biochemistry measurements and demographic information were obtained within 12 h of admission to hospital. Multivariable logistic regression analyses were performed to assess the predictors of thyroid dysfunction and Cox proportional hazards analyses were utilised to compare all-cause mortality by categories of thyroid dysfunction up to June 2019. Of the 1802 participants analysed, 1440 (79.9%) were euthyroid, 312 (17.3%) had subclinical hypothyroidism (SCH), 22 (1.2%) had subclinical hyperthyroidism (SHyper) and 25 (1.3%) had low T3 syndrome (LT3S). Predictors for SCH were increasing age, female sex, higher thyroid peroxidase antibody (TPOAb) levels, higher serum creatinine levels and early morning sampling time (between 00:01-06:00 h). The predictors of SHyper were lower body mass index and afternoon sampling time (between 12:01 and 18:00 h). Predictors of LT3S were increasing age, higher creatinine levels and presence of previous ischaemic heart disease. Compared to the euthyroid group, patients with LT3S had higher all-cause mortality; adjusted hazard ratio (95% CI) of 2.02 (1.03-3.95), p = 0.04, whereas those with SCH and SHyper did not exhibit significantly increased mortality; adjusted hazard ratios (95% CI) of 1.05 (0.74-1.49), p = 0.79 and 0.27 (0.04-1.95), p = 0.19, respectively. Thyroid dysfunction is common in AMI patients on admission to hospital and our data provide an understanding regarding which factors might influence thyroid dysfunction in these patients. Furthermore, the negative association between LT3S and increased mortality post-AMI has once again been highlighted by this study. More research is required to assess if treatment of thyroid dysfunction improves clinical outcomes.

Identifiants

pubmed: 32897534
doi: 10.1007/s40618-020-01408-0
pii: 10.1007/s40618-020-01408-0
pmc: PMC8124048
doi:

Substances chimiques

Autoantibodies 0
anti-thyroid autoantibodies 0
Creatinine AYI8EX34EU
Thyroxine Q51BO43MG4

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1209-1218

Subventions

Organisme : Department of Health
ID : CDF-2012-05-231
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : CDF-2012-05-231

Références

Arch Intern Med. 2012 May 28;172(10):799-809
pubmed: 22529182
JAMA. 2010 Sep 22;304(12):1365-74
pubmed: 20858880
N Engl J Med. 2001 Feb 15;344(7):501-9
pubmed: 11172193
Am J Kidney Dis. 2016 Dec;68(6):923-932
pubmed: 27596516
Eur J Endocrinol. 2011 Jan;164(1):101-5
pubmed: 20930062
Int J Cardiol. 2012 Jun 28;158(1):103-4
pubmed: 22560494
Am J Med Sci. 2012 Jan;343(1):65-70
pubmed: 21876429
Clin Cardiol. 2009 Jul;32(7):380-5
pubmed: 19609889
JAMA. 2020 Jul 21;324(3):249-258
pubmed: 32692386
ISRN Endocrinol. 2011;2011:810251
pubmed: 22363888
Am J Med. 2001 Dec 15;111(9):699-703
pubmed: 11747849
Arch Med Sci. 2016 Aug 1;12(4):772-7
pubmed: 27478458
Lancet Diabetes Endocrinol. 2019 Jun;7(6):473-483
pubmed: 30797750
Clin Endocrinol (Oxf). 1995 Jul;43(1):55-68
pubmed: 7641412
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31769839
ESC Heart Fail. 2015 Mar;2(1):5-11
pubmed: 28834641
J Cardiol. 2018 Sep;72(3):215-219
pubmed: 29580665
Cardiovasc Drugs Ther. 2010 Jun;24(3):217-23
pubmed: 20645124
N Engl J Med. 1995 Dec 7;333(23):1522-7
pubmed: 7477166
Eur J Cardiothorac Surg. 2004 Oct;26(4):720-5
pubmed: 15450562
Circulation. 2006 Jul 4;114(1 Suppl):I245-50
pubmed: 16820580
Int J Endocrinol. 2018 Nov 14;2018:1871530
pubmed: 30538743
BMJ. 2009 Mar 26;338:b725
pubmed: 19325179
J Clin Endocrinol Metab. 2011 May;96(5):1344-51
pubmed: 21346066
Intern Med. 2012;51(21):3009-15
pubmed: 23124142
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
J Clin Endocrinol Metab. 2012 Nov;97(11):3944-50
pubmed: 22879629
Thyroid. 2003 Nov;13(11):1069-78
pubmed: 14651790
Arch Intern Med. 2000 Feb 28;160(4):526-34
pubmed: 10695693
J Clin Endocrinol Metab. 2008 Apr;93(4):1351-8
pubmed: 18171701
Thyroid. 2013 Jun;23(6):654-61
pubmed: 23281965
Endocr Rev. 2008 Feb;29(1):76-131
pubmed: 17991805
Am J Cardiol. 2019 Mar 15;123(6):905-912
pubmed: 30638544
Clin Endocrinol (Oxf). 2012 Nov;77(5):773-9
pubmed: 22703566
Trials. 2015 Mar 25;16:115
pubmed: 25872532
J Thyroid Res. 2018 Sep 4;2018:9030185
pubmed: 30254730
Thyroid. 2015 Aug;25(8):954-61
pubmed: 26061389
Circulation. 2003 Feb 11;107(5):708-13
pubmed: 12578873
J Clin Endocrinol Metab. 2002 Feb;87(2):489-99
pubmed: 11836274
Thyroid. 2016 Sep;26(9):1195-204
pubmed: 27484151
J Clin Endocrinol Metab. 2013 Mar;98(3):1147-53
pubmed: 23345094
Isr Med Assoc J. 2019 Oct;21(10):692-695
pubmed: 31599513
Eur J Endocrinol. 2011 Jul;165(1):107-14
pubmed: 21490121
Arch Intern Med. 2007 Jul 23;167(14):1526-32
pubmed: 17646607

Auteurs

A Jabbar (A)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE1 3BZ, UK.
Department of Cardiology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

L Ingoe (L)

Department of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, UK.

H Thomas (H)

Department of Cardiology, Northumbria Healthcare NHS Foundation Trust, Cramlington, UK.

P Carey (P)

Department of Endocrinology and Cardiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.

S Junejo (S)

Department of Endocrinology and Cardiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.

C Addison (C)

Department of Biochemistry, South of Tyne Pathology Centre, Gateshead Health NHS Foundation Trust, Gateshead, UK.

J Vernazza (J)

Department of Biochemistry, South of Tyne Pathology Centre, Gateshead Health NHS Foundation Trust, Gateshead, UK.

D Austin (D)

Department of Cardiology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.

J P Greenwood (JP)

Leeds University and Leeds Teaching Hospitals NHS Trust, Leeds, UK.

A Zaman (A)

Department of Cardiology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

S Razvi (S)

Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE1 3BZ, UK. salman.razvi@ncl.ac.uk.
Department of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, UK. salman.razvi@ncl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH